

**PATIENT**

Montego Chamberlain

**SPECIES**

Canine

**BREED**

Labrador

**SEX**

Male Neutered

**AGE**

2.20.09

**WEIGHT**

104.6

**INTERPRETED BY**Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)**HOSPITAL NAME**Taylorsville Veterinary  
Clinic**REFERRING VET**

Dr. Earp

**INVOICE**

23493

**DATE**

4.6.22

**PRESENTING CLINICAL SIGNS**

History: Mild ALP elevation. T4 slightly low.

-Pertinent abnormal PE/Chem/CBC/UA Results: ALP is mildly elevated 240 U/L (5-160), T4 is slightly low 0.7 ug/dL (1-4).

-Radiographs: Heart appears displaced to the left. Ascites noted on brief AUS.

-Current medications: None listed.

-Blood pressure:

-Sedation used: Not required to complete full diagnostic ultrasound.

-Pertinent previous ultrasound results: No previous.

-STAT: Recommended by Sonographer based on findings, declined by DVM.

-Imaging performed by: Andi Parkinson, RDMS.

**ECHOCARDIOGRAM FINDINGS**

2D, m-mode, color flow and doppler imaging is available. Marked left ventricular dilation with diminished systolic function and increased sphericity. Hypokinetic free wall. Decreased LV wall thickness. Severe left atrial enlargement. The mitral valve appears mildly thickened with no obvious prolapse into the left atrial lumen. Moderate eccentric mitral regurgitation. Tricuspid valve appears mildly thickened. Moderate right atrial and ventricular dilation. Mild tricuspid regurgitation. TR velocity is normal. The aortic valve is normal in morphology and mobility. No subvalvular ridge present. Decreased LVOT and RVOT velocities. No aortic or pulmonic insufficiency. Normal RVOT velocity. No pericardial and scant pleural effusion noted. No obvious cardiac tumors.

**CARDIAC CHART**

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	4.1	2.5	NM	2.1	8	18	NM
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	196	0.8	0.4	47.4	4.1	6.7	6.1
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
<b>BODY WEIGHT DEPENDENT PARAMETERS</b>				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

Adapted from June Boon, Veterinary Echocardiography, 1998  
Rishniw M and Hollis NE, J Vet Intern Med 2000; 14:429-435  
Hansson et al, Vet Rad and Ultrasound 2002  
Bonagura et al. Echocardiography: principles of interpretation, Vet Clin North Am 15:1177, 1995

## INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Unfortunately, this patient has end-stage cardiomyopathy and systolic dysfunction. This is causing dilation and volume overload of both the left and right heart resulting in insufficiency of the mitral and tricuspid valves. The severity of dysfunction and pump failure is marked, and the patient is at exceedingly high risk for decompensating into congestive failure. Patient will always be at risk for right and/or left-sided CHF, development of arrhythmias/syncope and/or sudden death going forward.

Systolic failure can be primary in nature (DCM) or secondary to taurine deficiency, myocarditis, tachycardia-induced cardiomyopathy, or infiltrative disease such as lymphoma. In a senior lab, primary disease is possible; however, consider testing for causes that may be treatable. A troponin (cTnI) level can be submitted to further investigate infiltrative/inflammatory contribution (myocarditis). Additionally, a taurine level may be helpful (screen for malabsorption issue), and a thorough diet history given the recent correlation with grain free/boutique brand/exotic ingredient diets. Finally, further systemic evaluation for underlying infiltrative contribution such as neoplasia is also reasonable (abdominal ultrasound, etc.). Regardless of cause, prognosis is guarded to poor at this stage in the disease process, with an average survival time of <6 months. The only treatable cause of systolic failure is diet/taurine deficiency, which is uncommon on commercially formulated dog foods. If the diet is of concern, highly recommend immediate diet change and taurine supplement regardless of blood taurine results. Please see the FDA website for more information.

Immediate institution of full cardiac supportive medications is recommended as below including Lasix therapy due to presence of effusion. Cases of systolic failure are at high risk for malignant tachyarrhythmias (such as VT or rapid AF) and sudden death, and this should be expressed to the owner. Activity restriction is advised, and a baseline ECG recommended, particularly given that the patient is tachycardic.

Elective anesthesia is not advised due to exceedingly high risk for complications.

Omega fatty acid supplementation and mild salt restriction may be of some long-term benefit. Monitor for development of a cough, worsening labored breathing, abdominal distention, exercise intolerance or collapse episodes in the future. Monitoring of sleeping breathing rates at home is recommended to assess response to medications and recurrence of CHF in the future.


### PLAN:

Baseline ECG and BP are recommended. Initiate aldosterone antagonist Spironolactone 1-2mg/kg PO q12h. Institute furosemide 1-2mg/kg PO q12h. Institute Pimobendan 0.3mg/kg PO q12h. Institute taurine 1000mg PO q12h. Diet history/change, thyroid level, etc. as discussed.

Monitor a renal panel and blood pressure in 1-2 weeks to ensure tolerance. If BP >130mmHg, institute ACEI 0.5mg/kg PO q12h. Consider cTnI, taurine level, AUS as discussed above.

A recheck echocardiogram is recommended in 4-6 months to screen for progression, sooner if clinical issues arise in the interim.

### IMAGES



**The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.**

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

**Maggie Machen Lamy, DVM**  
**Diplomate of the American College of Veterinary Internal Medicine (Cardiology)**  
**info@sonopath.com**